Introducing the Nu.Q™ Vet Cancer Screening Test for Pet Owners
With approximately 77 million pet dogs in the United States, there are an estimated 6 million pet dogs diagnosed with cancer each year. Earlier detection of cancer can not only help save lives, it can also improve the quality of life of the dog and more quality time with its owner.

Yet, as of today, unlike the human healthcare world where screening for certain cancers is commonplace (mammogram for breast cancer, colonoscopy for colorectal cancer, HPV for cervical cancer, to name but a few) there are few cancer screening tests on the veterinary market. Currently, many dogs are only diagnosed when they are unwell and there is a suspicion of cancer. Even then dogs suspected of having cancer are required to undergo a variety of diagnostic tests that may be expensive, time consuming and/or painful for the animal.

We hope to change this with the introduction of the Nu.Q™ Vet Cancer Screening Test – a simple, low-cost, easy to use screening blood test to be used with the annual wellness check for older dogs (7 years and older), or for cases where there is a high suspicion of cancer.

It may also be a complementary test for younger dogs at high risk for developing cancer in their lifetimes such as, Golden Retrievers, Boxers, Flat Coated Retrievers, Beagles, Burmese Mountain dogs, Rottweilers, West Highland White Terriers and Shetland Sheepdogs as they age.

The Nu.Q™ Vet Cancer Screening Test has been shown to detect lymphoma and hemangiosarcoma, common cancers which make up approximately one third of canine cancers.

We believe using the Nu.Q™ Vet Cancer Screening Test can help streamline the diagnostic process and shorten the path to diagnosis thereby allowing treatment (be that therapy or surgery) to be initiated earlier.

The benefit for the veterinarian, the pet owner and the dog is a streamlined diagnostic process: simpler, quicker and less painful diagnosis with the goal of providing quality of life to the pet and more quality time with its owners, as well as providing valuable additional information to inform the clinical decision-making process.

This revolutionary product has been developed in collaboration with Texas A&M University and the results of key studies were presented at the world’s largest Veterinary Oncology Meeting, the Veterinary Cancer Society Conference in October 2020.